[Application progress of macrolide sustained therapy for bronchiectasis].
Lichao
L
Fan
Email: jfxucn@gmail.com.
Jinfu
J
Xu
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001980:Bronchi / Q000378:metabolism / Q000503:physiopathology; D001987:Bronchiectasis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001988:Bronchiolitis / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D016207:Cytokines / Q000378:metabolism; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000008:administration & dosage / Q000627:therapeutic use*; D005541:Forced Expiratory Volume; D006801:Humans; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D018942:Macrolides; D014409:Tumor Necrosis Factor-alpha; D004917:Erythromycin